Author: admin

  • Fetal Brain Genes May Drive Later Brain Disorders

    Fetal Brain Genes May Drive Later Brain Disorders


    Register for free to listen to this article

    Thank you. Listen to this article using the player above.


    Want to listen to this article for FREE?


    Complete the form below to unlock access to ALL audio articles.

    A new study by researchers at the Hospital del Mar Research Institute and Yale University suggests that the origins of several brain-related disorders may be found in the earliest stages of fetal brain development. The findings, published in Nature Communications, show that many genes associated with neuropsychiatric and neurodegenerative diseases are active in neural stem cells, well before birth.

    The research focused on nearly 3,000 genes linked to conditions such as autism, bipolar disorder, depression, schizophrenia and neurodegenerative diseases including Alzheimer’s and Parkinson’s. Using a combination of human and mouse data, alongside in vitro cellular models, the team simulated how genetic disruptions might affect the development of the fetal brain.

    Simulating genetic disruptions in neural stem cells

    Neural stem cells give rise to all the cell types of the brain, including neurons and their support cells. The study explored how gene alterations influence these progenitor cells during different stages of development. Researchers modelled regulatory networks for each relevant cell type and assessed how activating or silencing disease-linked genes affected their behaviour.

    Neural stem cells

    These are self-renewing cells in the developing brain that generate neurons and glial cells. They play a crucial role in forming brain structures during fetal development.

    Regulatory networks

    In biology, these are systems of interacting genes, proteins, and other molecules that control gene expression and cellular behaviour. They are key to understanding how genes function in specific contexts.

    This approach allowed the team to identify when and where specific genes are most active, providing a clearer picture of how early genetic alterations may lead to brain structure and function changes later in life. Disorders ranging from cortical malformations, such as microcephaly and hydrocephaly, to anorexia, depression and schizophrenia were included in the analysis.

    “Scientists usually study the genes of mental illnesses in adults, but in this work we discovered that many of these genes already act during the early stages of fetal brain formation, and that their alterations can affect brain development and promote mental disorders later on”.

    Dr. Nicola Micali.

    Cortical malformations

    These refer to structural abnormalities in the cerebral cortex, the brain’s outer layer, which can lead to neurological and developmental disorders.

    Broader implications for understanding disease mechanisms

    The study suggests that disruptions to gene function in neural stem cells could contribute to a wide range of conditions affecting the cerebral cortex. It also highlights specific developmental windows when these genes are especially influential, which could be critical for identifying periods of heightened vulnerability or therapeutic opportunity.

    The findings may contribute to future efforts in understanding how early brain development impacts mental and neurological health. They also lay the groundwork for more targeted studies into gene function during neurodevelopment, potentially informing future gene-based treatment approaches.

    Reference: Mato-Blanco X, Kim SK, Jourdon A, et al. Early developmental origins of cortical disorders modeled in human neural stem cells. Nat Commun. 2025;16(1). doi: 10.1038/s41467-025-61316-w

    This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

    This content includes text that has been generated with the assistance of AI. Technology Networks’ AI policy can be found here.

    Continue Reading

  • Former UCI President suffers heart scare

    Former UCI President suffers heart scare

    Brian Cookson, a former president of both the UCI and British Cycling, says participating in a recent study into heart scarring could have saved his life after he experienced an “unusual episode” while training at the Manchester Velodrome last year.

    The 74-year-old has remained an avid cyclist since retiring and has regularly competed at a variety of events – including in the Gran Fondo World Championships.

    Continue Reading

  • Jazz fans, take note: this audiophile record label’s full hi-res catalogue is now available on Qobuz

    Jazz fans, take note: this audiophile record label’s full hi-res catalogue is now available on Qobuz

    Ron Carter, Peggy Lee, Jimmy Cobb, Macy Gray, The Persuasions – if those names ignite your musical senses, then we have good news.

    Chesky Records is an independent record label that specialises in high-definition recordings and whose genres span classical, jazz, soul, blues, folk and more, and its full catalogue is now fully available to stream and download hi-res music streaming platform Qobuz.

    Continue Reading

  • Chrome’s AI Challenger Has Landed: Meet Comet

    Chrome’s AI Challenger Has Landed: Meet Comet

    Agentic AI
    ,
    Artificial Intelligence & Machine Learning
    ,
    Next-Generation Technologies & Secure Development

    Perplexity’s Comet Blends Familiarity With Agentic AI to Reshape the Web

    Image: Shutterstock

    Perplexity, the fast-rising artificial intelligence search engine startup backed by the likes of Nvidia and Jeff Bezos, is riding on a cosmic high with the launch of Comet – a full-featured AI-native web browser that claims to “browse at the speed of thought.”

    See Also: OnDemand Webinar | Trends, Threats and Expert Takeaways: 2025 Global IR Report Insights

    Currently in beta and invite-only for premium users, Comet is positioned as the next interface layer between users and the internet. Built on Chromium, the open-source framework behind Chrome and Edge, it integrates Perplexity’s search engine and generative AI directly into the browsing experience.

    For Aravind Srinivas, the 31-year-old founder of the $18 billion startup, it could be the “killer app” for AI.

    And it’s caused a bit of a stir.

    “Don’t count Comet out,” said John B. Dickson, CEO of Bytewhisper Security. “In the early 2000s, Yahoo, AltaVista and other browser companies didn’t take Google seriously enough and look where they are now.”

    Unlike traditional browsers, Comet is “memory-native,” designed to retain contextual understanding across sessions, tasks and prompts – an early attempt at solving what Srinivas calls the “personal intelligence” problem.

    The AI-powered browser blends the speed and familiarity of Chrome with a fine-grained, agentic model of user interaction. The result is a browser that reads, reasons and acts, collapsing navigation, search and task execution into a conversation-like stream.

    The vision is straightforward. “There shouldn’t be a need for the user to figure out when to use what tool or the countless modes in it. Everything should blend together like a perfectly played orchestra,” Srinivas said.

    That is what Comet attempts to do. Users do not have to click through layers of menus or manually switch between sites, simply prompting an agent that can act across their online activities. Whether it’s pulling relevant emails ahead of a scheduled call, rebooking travel or finding a document buried in a cloud drive, Comet introduces workflows where intent is expressed in natural language and results are synthesized and executed by the browser itself.

    This functional overlay of intelligence represents a shift in what a browser is expected to do.

    In fact, Srinivas anticipates Comet will eventually automate at least two white-collar roles inside every company: recruiters and administrative assistants. In the short term, this may appeal to enterprises looking for productivity gains.

    Is Chrome Cooked?

    There’s a strategic vulnerability in Chrome: It was never built to be agentic. Retrofitting AI into legacy interfaces often leads to awkward user experiences. Comet’s strength is in being designed AI-first, and not as an AI-afterthought.

    But there’s a reason why Chrome is still the default gateway for over 3.7 billion users. It works. It’s reliable. It doesn’t guess, embellish or improvise.

    AI does.

    “Large language models are fundamentally generative – unlike the results page in traditional ‘Googling,’ AI will literally make up a response that it hopes is real and correct,” said Kyle Hankins, CTO and co-founder of Bytewhisper Security.

    “Agentic AI carries all the same challenges, with the added risk of real consequences for its mistakes – booked trips, purchased products, cancelled meetings.”

    Nevertheless, the race is on, and Perplexity is not the only candidate.

    OpenAI is also rumored to be building its own browser as a rival to Chrome, designed to “keep some user interactions within a ChatGPT-like native chat interface instead of clicking through to websites,” Reuters reported. Meanwhile, other AI-native browsers such as Dia are experimenting with similar concepts. Legacy player Google isn’t sitting idle either – it’s baking AI into its own products through Gemini and Search Generative Experience. The arms race is on, and Comet will need more than clever UX to tip the scales.

    These parallel efforts suggest that the next phase of AI integration will unfold in the browser layer, rather than in isolated apps or chatbots.

    But for putting agentic AI to use, Perplexity may have an edge.

    “The browser might be the best way to build agents,” Srinivas said in a podcast with The Verge.

    That premise – one part insight, one part strategy – has helped shape Comet into what could be one of the most disruptive experiments in web infrastructure since Google Chrome launched in 2008.

    But then, again, Chrome was always free. As Dickson said, “Perplexity’s agent will have to stand head and shoulders above others in a world where ‘free’ still beats $200/month in fees.”

    A Bid for the Browser Default

    Comet is currently restricted to desktop environments, but Perplexity is actively negotiating with smartphone makers to expand its reach. According to a recent Reuters report, the company is in talks with mobile device manufacturers, including Samsung and Apple, to pre-install Comet or integrate its AI capabilities into digital assistants such as Bixby or Siri at scale.

    This strategy could expand Perplexity’s user base by leveraging “browser stickiness” – a tendency of users to continue using browsers that come pre-installed or are set as the default on their devices. But Srinivas admits it’s “not easy” to convince mobile OEMs to change the default browser to Comet from Chrome.

    The company is targeting “tens to hundreds of millions” of users in the coming year. That projection rests heavily on its ability to finalize deals with phone makers and demonstrate reliability.

    The high expectations are bolstered by the meteoric rise of Perplexity, with investors such as Accel, Nvidia, Jeff Bezos and Eric Schmidt.

    And if it succeeds, Comet won’t just be a new browser. It will be a new interface for the internet itself.

    But as with any celestial event, the question still is: Will Comet burn bright or quickly fade into obscurity?

    “The tech is sleek. The ambition is high. The investors are A-list, but this launch feels like classic ‘throw-it-and-see-what-sticks,’” said Chaitra Vedullapalli, co-founder of Women in Cloud.

    “It’s branded as a comet: fast, fiery and unforgettable. But real comet behavior? Some destroy, some just flash and fade, only a few shape the cosmos. Right now, it’s unclear which one Comet will be,” Vedullapalli said.

    Continue Reading

  • Number of adults prescribed ADHD medication rises by a quarter

    Number of adults prescribed ADHD medication rises by a quarter

    The number of adults in England prescribed medication for attention deficit hyperactivity disorder (ADHD) has risen by almost a quarter in the past year, NHS Business Services Authority Digital (NHS BSA) data show.

    According to data published by NHS BSA on 24 July 2025, 190,000 adults were prescribed central nervous system (CNS) stimulants and drugs for ADHD in 2024/2025, a 24.3% increase from 2023/2024.

    In 2024/2025, 135,000 children were prescribed CNS stimulants and drugs for ADHD, an increase of 9.5% since 2023/2024, the data revealed.

    A total of 71,047 patients who were prescribed ADHD medication in 2024/2025 were aged 10–14 years, accounting for more than a third of the total number of prescriptions.

    A total of 38 patients aged 0–4 years received ADHD medication in 2024/2025, while 48 patients were aged 90 years or over.

    Data covering the past ten years show that the number of identified patients receiving prescriptions for ADHD has more than trebled.

    In 2015/2016, there were 107,155 identified patients, which rose to 326,450 in 2024/2025, the ten-year data show.

    The data also indicated an increase in the number of women receiving prescriptions for ADHD.

    In 2015/2016, women made up 24% of identified patients, while in 2024/25 this figure had risen to 38%.

    There have been persistent shortages of ADHD medicines in the UK since 2022, owing to increased global demand and manufacturing issues, which pharmacists have warned can put patients at risk.

    Henry Shelford, chief executive of the charity ADHD UK, said: “The increase in people receiving an ADHD diagnosis and medication should be celebrated, especially as many will have waited years to get to this point. Each data point is an individual now getting help they need.

    “These ADHD diagnoses and support mean lives turned around, careers rehabilitated, people moving out of crisis, out of destitution, into work and off benefits. Undiagnosed ADHD is costing the UK billions, costing individuals their livelihood and sometimes their lives. These figures represent a positive step forward, but with so many still undiagnosed, there is still a lot of work to be done.”

    Shelford said that “the proportional increase in women and girls receiving ADHD medication underlines the historical and ongoing failure to recognise ADHD in women and girls”.

    “Girls with ADHD are disproportionately missed in schools and too often then face a fight for adult recognition,” he added.

    “ADHD patient recognition and assessment in this country is not fit for purpose and requires a systemic overhaul.”

    Khadija Mansoorali, paediatric mental health pharmacist at the Royal Manchester Children’s Hospital, said that, in recent years, there has been “greater recognition around ADHD and neurodiversity in general”.

    “Information is increasingly accessible, which may help people to recognise some of the signs and symptoms of ADHD. This could be via official health platforms, or even through social media. This could lead to further referrals for assessment, leading to diagnosis.”

    Mansoorali added that pharmacists “are in a key position to be able to offer safe and reliable advice to patients and prescribers regarding shortages”.

    “We are often aware of the preparations that are available and can offer support to prescribers,” she said.

    “Pharmacy teams can also offer support by counselling patients on medication and recognising potential side effects. Pharmacy teams should be skilled in using neuro-affirmative language to provide tailored care that respects each patient’s unique needs.”

    The NHS BSA data also show that antidepressant prescriptions continue to rise, with 8.9 million identified patients receiving a prescription in 2024/2025, an increase of 1.6% compared with 2023/2024.

    In addition, the number of identified patients prescribed drugs for dementia has risen by 5.4% since 2023/2024 to 326,000 patients. NHS BSA noted that dementia was the only condition for which prescribing was higher in least deprived areas.  

    Continue Reading

  • Fetal Bradycardia in last trimester imposed as fetal distress: Case Re

    Fetal Bradycardia in last trimester imposed as fetal distress: Case Re

    Introduction

    Congenital heart disease (CHD) is the most common fatal congenital anomaly in newborns, representing around one-third of all birth defects.1 Each year, approximately 1.5 million children are affected by CHD.2 Although the prevalence of CHD may remain unchanged, enhancing screening efforts, allocating adequate resources, and implementing effective interventions are essential to improving survival rates and long-term outcomes. Furthermore, mortality has risen in recent decades, particularly in low- and middle-income countries, due to insufficient diagnostic and treatment infrastructure.3

    Over the past two decades, advances in imaging technology have significantly improved the prenatal evaluation of fetal cardiovascular structures.4 Most CHD cases can now be detected through obstetric ultrasound, particularly when incorporating four-chamber (4C) and outflow tract views, achieving sensitivities of up to 85%.5,6

    Prenatal diagnosis of CHD plays a critical role in parental counseling, multidisciplinary planning of perinatal care, timely referral to tertiary care centers, and potentially improving neonatal outcomes.7 However, despite these advancements, only up to 40% of CHD cases are diagnosed prenatally in routine practice, even in low-risk populations.8 In developing countries, the situation is more challenging due to limited access to qualified clinicians, fetal echocardiography, and referral systems, particularly in remote areas.

    Referral for detailed fetal echocardiography is recommended when a cardiac anomaly is suspected, especially if bradycardia or rhythm disturbances are observed.8 Fetal bradycardia, as presented in this case, can be easily misinterpreted as non-specific fetal distress, leading to delayed or missed diagnosis of underlying complex congenital heart disease. Highlighting this misdiagnosis underscores the importance of distinguishing between fetal bradycardia due to conduction abnormalities and true fetal distress in prenatal care. This case report uniquely contributes to the literature by highlighting the diagnostic challenges and clinical significance of fetal bradycardia as an early sign of complex CHD in a resource-limited setting. It underscores the need for heightened awareness and structured referral protocols even in low-resource areas. Additionally, it explores the possible underlying mechanisms linking bradycardia with fetal structural heart defects, supported by detailed case findings and echocardiographic evaluation.

    Case Report

    A 33-year-old pregnant woman was referred to a tertiary health-care center due to a suspected fetal heart abnormality. One week prior, she had undergone a routine antenatal check-up with a midwife in a local hospital in Sukabumi, West Java, where fetal distress was suspected based on an irregular fetal heart rate. At the local hospital, she denied any obstetric complaints such as labor pains or bloody show. She reported positive fetal movements. Ultrasonography (USG) revealed a single live fetus in cephalic presentation corresponding to 29–30 weeks of gestation based on transverse cerebellar diameter (TCD: 29 weeks 3 days). The fetal heart rate was irregular, the placenta was anteriorly located, estimated fetal weight (EFW) was 1387 grams, and the single deepest pocket (SDP) of amniotic fluid measured 5.67 cm (Figure 1). Cardiotocography (CTG) showed a non-reassuring tracing (Type II). Given the limitations in diagnostic capability and neonatal support at the local facility, the patient was referred to our tertiary center.

    Figure 1 Fetal echocardiography. (A) Biparietal diameter; (B) abdominal circumference; (C) fetal length; (D) cerebellum; (E) thorax appearance; (F) mitral valve abnormality.

    At admission, the patient reported no complaints. Her vital signs were within normal limits. Her pre-pregnancy body weight was 62 kg, current weight 74 kg, and height 145 cm, resulting in a body mass index (BMI) of 35.1 kg/m². Obstetric examination revealed a soft, convex abdomen with a fundal height of 22 cm and abdominal circumference of 95 cm. The fetus was in breech lie with an estimated weight of 1300 grams, and the fetal heart rate ranged between 88–92 beats per minute (bpm).

    Obstetric history revealed this was her third pregnancy: her first, 12 years prior, resulted in spontaneous vaginal delivery of a 2300-gram baby in breech presentation; her second was a miscarriage at 5 weeks’ gestation. She is currently in her first pregnancy with her current husband. She had been receiving regular antenatal care with a midwife. There was no relevant maternal medical history, including collagen vascular disease, and no known family history or environmental exposure to teratogens.

    Fetal echocardiography revealed multiple congenital cardiac anomalies: atrioventricular septal defect (AVSD), tricuspid regurgitation (peak velocity 70 cm/s), mitral valve abnormalities, suspected aortic and pulmonary artery stenosis, and atrioventricular conduction abnormalities. Additional findings included a 7.5 mm ventricular septal defect (VSD), pericardial effusion, and discordant atrial and ventricular heart rates (atrial: 135 bpm; ventricular: 93 bpm). The cardiothoracic area ratio (CTAR) was 28%, and cardiac axis was 58.9 degrees. Doppler velocimetry results were: umbilical artery pulsatility index (PI) 2.12; middle cerebral artery PI 2.34; right uterine artery PI 0.81; left uterine artery PI 0.63, with no notching observed.

    Her final diagnosis was G3P1A1 29 weeks 3 days of pregnancy; breech lie; Fetal congenital heart disease (atrioventricular septal defect, tricuspid regurgitation, mitral valve abnormality, suspect aortic and pulmonary artery stenosis, atrioventricular conduction abnormality). After thorough counseling, the patient wished to continue the pregnancy. She later gave birth to a baby girl at local hospital. Unfortunately, the neonate died from cardiac arrest on the second day of life.

    Discussion

    Congenital arrhythmias may serve as a vital clue for identifying congenital heart disease (CHD) in fetuses, as demonstrated in this case. CHD remains the most common congenital malformation, affecting approximately 8–9 per 1,000 live births.9 Most cases can now be diagnosed prenatally through obstetric ultrasonography, particularly during detailed fetal anomaly screening at 20–24 weeks gestation.5 Assessment of fetal dysrhythmias is usually based on ultrasound to determine fetal well-being, assess cardiac structures, and define the nature of rhythm disturbance with confidence to decide whether in-utero treatment is needed.5 Examination of the fetal heart and cardiovascular system has evolved considerably over the past 2 decades, mostly as a result of advances in imaging technology. The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) recommends a standardized fetal cardiac screening protocol, including four-chamber (4C), left and right ventricular outflow tract, and three-vessel views.10

    In this case, bradycardia was noted at the first examination and prompted further cardiac evaluation. According to the American College of Obstetricians and Gynecologists (ACOG), fetal bradycardia is defined as a fetal heart rate (FHR) < 110 beats per minute (bpm).11 Persistent bradycardia often indicates conduction abnormalities, such as atrioventricular block (AVB), particularly when associated with structural CHD. The high degree or complete AVB is one of the most dangerous fetal bradyarrhythmias due to increased fetal loss risk. It occurs when the beat of the atria is completely dissociated from the ventricular beat and causes significant bradycardia with an FHR of up to 40–90 bpm. It is common and has two predominant presentations: (1) fetus with normal cardiac structure and exposure to specific maternal autoantibodies (immune-mediated AVB), and (2) AVB can be present in fetuses with complex CHD, like in the case presented.12

    Structural heart defects associated with AVB often appear earlier in gestation, commonly before the fifteenth week of gestation. However, it does not mean it will not be detected later, such as in this case. The most frequent cardiac malformations are left atrial isomerism (LAI), congenitally corrected transposition of the great arteries (CC-TGA), atrioventricular septal defect (AVSD) such as in this case, double outlet right ventricle (DORV); and tetralogy of Fallot (TOF).12 These conditions often result from mutations in genes encoding for transcription factors critical for cardiac chamber formation, endocardial cushion remodeling, and conduction system development (ie, Nkx2-5, Tbx5, and Id2).12

    In this case, the fetus demonstrated complex CHD, including AVSD, tricuspid regurgitation, mitral valve abnormality, suspected aortic and pulmonary stenosis, and AV conduction abnormality—all visible through the 4C view. The 4C view is fundamental for fetal cardiac screening, as it enables evaluation of cardiac position, size (ideally one-third of the thoracic cavity), contractility, and rhythm. In a normally positioned heart (levocardia), two-thirds of the heart lies on the left side, with an axis angled approximately 45 ± 20 degrees. A deviation in this axis may be associated with chromosomal anomalies, congenital diaphragmatic hernia, or complex CHD—especially conotruncal anomalies and single-ventricle hearts.

    This view also allows for detailed morphological and functional assessment of each cardiac chamber and the atrioventricular valves. The left atrium (LA) is normally located most posteriorly (near descending aorta), and the finger-like appendage identifies it. Furthermore, the LA is characterized by the presence of the foramen ovale flap and its connection with the pulmonary veins. The right atrium (RA) has a pyramidal appendage with a broad base and receives the vena cava.8

    Despite advances in imaging, prenatal sonographic diagnosis of CHD remains challenging. Accurate diagnosis requires multidisciplinary collaboration among sonographers, obstetricians, radiologists, and specialists in fetal medicine. When a fetus is at high risk for cardiac anomalies or a structural abnormality is suspected during routine obstetric ultrasound—even in low-risk pregnancies—a referral for comprehensive fetal echocardiography is recommended. In many cases, evaluation at a tertiary care center is necessary to thoroughly assess fetal cardiac anatomy, monitor fetal condition, and determine whether in-utero intervention is warranted.13

    Intrauterine detection of CHD relies on several factors, such as accessible health care. Libermann et al originally highlighted delays in CHD detection in non-tertiary settings due to limited fetal cardiology services.13 Compared to a decade ago, some improvements in the availability of prenatal diagnostic tools have been made in rural areas, including the use of portable ultrasound and telehealth services; however, significant disparities remain. Although even in most developed areas, detection rates are low, distant access might aggravate this condition, thus causing detection rates in less developed areas even lower, such as in this case. The sonographer’s expertise in the assessment of the fetal heart also played a role in the diagnosis of CHD. A high proportion of CHD without prenatal diagnosis is seen in patients who underwent several ultrasounds that only report the fetal heart rate without assessing the fetal heart anatomy.

    In this case, although multiple routine ultrasounds were performed, earlier signs of CHD may have been missed. Literature suggests that many undetected CHD cases result from fetal ultrasounds reporting only the FHR without anatomical assessment. A structured approach using both 4C and outflow tract views improves detection rates to 70–85%.6 However, access remains limited in remote regions, and CHD continues to be underdiagnosed during routine prenatal care.

    Referral to a tertiary center is crucial when CHD is suspected, both for detailed fetal echocardiography and to plan delivery at a facility equipped for neonatal cardiac care. In this case, delayed diagnosis and lack of early referral limited the available perinatal options. Delivery in or near a tertiary center is recommended for patients requiring early intervention, of which many can be identified in advance.

    Conclusion

    Fetal bradycardia may serve as an early sign of congenital heart disease (CHD), emphasizing the importance of detailed prenatal cardiac evaluation. This case underscores the need for improved access to fetal cardiac screening and trained personnel, particularly in rural settings. Expanding anatomical assessments and strengthening referral systems to tertiary centers can support earlier diagnosis and better perinatal outcomes.

    Ethical Approval

    No formal ethical clearance was required for the publication of this case. The authors confirm that written informed consent for publication of this case report and any accompanying images were obtained from the patient and her spouse. The patient was informed in detail about the case content and agreed to its publication. All personal identifiers have been removed to ensure patient anonymity.

    Informed Consent Patient Statement

    Written informed consent was obtained from the patient for publication of this case report and any accompanying images. The patient(s) has been informed about the details of the case and has provided approval for the information to be published in this case report (series). A copy of the written consent is available for review by the Editor upon request.

    Patient’s Perspective

    After learning about the possible abnormalities in my fetus, I chose to continue with the pregnancy because I believed it was the best decision for me and my family. I felt that my pregnancy was progressing well, despite concerns about the fetus’s condition. I trusted that I could handle this situation. After being informed about the possible heart abnormalities in the fetus, I felt anxious, but I chose not to follow up with the doctor at the tertiary health-care facility because I felt I had received enough explanation. I decided to deliver my baby at the hospital closest to my home, hoping everything would go smoothly. However, a few days after giving birth, I was devastated and felt a profound loss when my baby passed away. I feel sad and confused, but I am trying to come to terms with this reality.

    Registration of Research Studies

    Registration of research is not applicable in our case.

    Author Contributions

    LR and ASN conceived the design in article and collected the data. LR and ASN wrote the draft. JSC and AP directed and supervise the review article. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

    Funding

    The study did not receive external funding.

    Disclosure

    The authors declare that they have no competing interests in this work.

    References

    1. Parvar SY, Ghaderpanah R, Naghshzan A. Prevalence of congenital heart disease according to the echocardiography findings in 8145 neonates, multicenter study in southern Iran. Health Sci Rep. 2023;6(4):e1178. doi:10.1002/hsr2.1178

    2. Mandalenakis Z, Giang KW, Eriksson P, et al. Survival in children with congenital heart disease: have we reached a peak at 97%? J Am Heart Assoc. 2020;9(22):e017704. doi:10.1161/JAHA.120.017704

    3. Zheleva B, Atwood JB. The invisible child: childhood heart disease in global health. Lancet, 389 10064 16–18 doi: 10.1016/S0140-6736(16)32185-7.

    4. Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation. 2014;129(21):2183–2242. doi:10.1161/01.cir.0000437597.44550.5d

    5. Carvalho JS. Fetal dysrhythmias. Best Pract Res Clin Obstet Gynaecol. 2019;58:28–41. doi:10.1016/j.bpobgyn.2019.01.002

    6. Pinto NM, Henry KA, Grobman WA, et al. Physician barriers and facilitators for screening for congenital heart disease with routine obstetric ultrasound: a national United States survey. J Ultrasound Med. 2020;39(6):1143–1153. doi:10.1002/jum.15199

    7. Meller CH, Grinenco S, Aiello H, et al. Congenital heart disease, prenatal diagnosis and management. Arch Argent Pediatr. 2020;118(2):e149–e61. doi:10.5546/aap.2020.eng.e149

    8. Bravo-Valenzuela NJ, Peixoto AB, Araujo Júnior E. Prenatal diagnosis of congenital heart disease: a review of current knowledge. Indian Heart J. 2018;70(1):150–164. doi:10.1016/j.ihj.2017.12.005

    9. Galvis MMO, Bhakta RT, Tarmahomed A, Mendez MD. Cyanotic heart disease. StatPearls Publishing; 2023.

    10. Carvalho J, Axt-Fliedner R, Chaoui R, et al. ISUOG Practice Guidelines (updated): fetal cardiac screening. Ultrasound Obstet Gynecol. 2023;61(6):788–803. doi:10.1002/uog.26224

    11. American College of Obstetricians and Gynecologists (ACOG). Prevention of infection after gynecologic procedures: ACOG practice bulletin. Number 195 Obstetrics Gynecol. 2018;131(6).

    12. Caruso E, Farruggio S, Agati S, Di Mambro C. Fetal bradyarrhythmias: etiopathogenesis, diagnosis and treatment: between literature review and experience of a tertiary center. Congenit Heart Dis. 2021;16(10.32604):309–331. doi:10.32604/CHD.2021.015470

    13. Liberman RF, Heinke D, Lin AE, et al. Trends in delayed diagnosis of critical congenital heart defects in an era of enhanced screening, 2004-2018. J Pediatr. 2023;257:113366. doi:10.1016/j.jpeds.2023.02.012

    Continue Reading

  • Heavyweights set to clash in the VNL semifinals – Volleyball World

    1. Heavyweights set to clash in the VNL semifinals  Volleyball World
    2. Everything you need to know about the VNL Women’s Finals  Volleyball World
    3. Brazil vs Japan: Epic Semi-Final Volleyball Clash  777Score
    4. U.S. Women Battle Before Falling to Italy in 2025 Volleyball Nations League Quarterfinal  USA Volleyball
    5. Lexi Rodriguez’s Match Record in Vain as USA Volleyball’s Thrilling VNL 2025 Journey Ends  EssentiallySports

    Continue Reading

  • Stockton MP criticises approval of Byers Gill solar farm

    Stockton MP criticises approval of Byers Gill solar farm

    Bill Edgar

    Local Democracy Reporting Service

    RWE  A big, flat grassy field with a tree on the horizon .RWE

    Byers Gill solar farm will have a lifespan of 40 years, after which it will be removed

    An MP says he is “disappointed and angry” over a government decision to approve a large, £200m solar farm.

    Conservative Matt Vickers, who represents Stockton West, has warned the Byers Gill Solar Farm near Darlington and Stockton will harm the local landscape.

    “It will damage our rich tapestry of wildlife and biodiversity and could have a huge impact on our village communities and food security,” Vickers said.

    The government said it would reduce bills and provide energy security, while developer RWE said the facility would be removed at the end of its estimated 40-year lifespan.

    Vickers previously spoke against the solar farm during a House of Commons debate in 2024, as large swathes of nearby greenbelt land have been obtained by developers for solar farms.

    According to the Local Democracy Reporting Service, the 180MW farm would be made up of several blocks of development located in Brafferton, Hauxley Farm, Byers Gill Wood, Great Stainton and two near Bishopton.

    RWE said the development will cover about 490 hectares (1,211 acres) of land in total.

    A mainly white map showing roads and the boundaries of fields, with areas in green to show where solar panels will be built.

    Byers Gill Solar Farm is made up of several blocks of development

    Speaking after the government’s decision to approved the plans, Vickers said: “Labour is so obsessed with net-zero and solar farms that they’re happy to bulldoze through the views of local residents to push ahead with it.”

    He claimed Labour “couldn’t give a damn about the views of local people”.

    But the energy consumers minister Miatta Fahnbulleh said: “Families in the North East have seen their energy bills go through the roof as a result of our exposure to volatile gas prices.

    “The only way to make British people better off in the long term is by securing clean, homegrown power that we control.”

    Continue Reading

  • Jaw-Dropping Video Shows NASA’s Plan to Deliver a Helicopter Swarm to Mars Without Landing

    Jaw-Dropping Video Shows NASA’s Plan to Deliver a Helicopter Swarm to Mars Without Landing

    It’s been more than a year since the Ingenuity helicopter broke one of its blades, ending its experimental stint on Mars. On the heels of this wildly successful NASA mission, a defense contractor has introduced a new design concept to succeed the iconic Mars chopper—one that would release multiple vehicles to spread across the Martian landscape at the same time, like a coordinated swim team diving into the water.

    Virginia-based AeroVironment (AV), in partnership with NASA’s Jet Propulsion Laboratory (JPL), recently revealed its Skyfall mission concept, a next-generation Mars helicopter designed to pave the way for a future human landing on the neighboring world. Skyfall would deploy six small choppers, similar to NASA’s Ingenuity, to the Red Planet using a single entry capsule, with each helicopter landing independently on the Martian surface. The mission is aiming for a launch date in 2028, according to AV.

    The landing carrier would drop the six helicopters midway through its descent through the planet’s atmosphere, eliminating the need for a landing platform. Following their release from the carrier, each helicopter would land on the Martian surface under its own power. Each helicopter would quickly get to work, exploring different parts of the planet and investigating potential landing sites for a future human mission.

    Operating independently, each chopper will collect high-resolution images of the surface and radar data from beneath the surface to search for potential resources on Mars. “With six helicopters, Skyfall offers a low-cost solution that multiplies the range we would cover, the data we would collect, and the scientific research we would conduct–making humanity’s first footprints on Mars meaningfully closer,” William Pomerantz, head of Space Ventures at AV, said in a statement.

    Ingenuity was the first helicopter to fly on another planet, paving the way for a fleet of successors that can explore the Martian surface from above. The o.g. Mars helicopter arrived on the planet in February 2021, tucked inside the belly of NASA’s Perseverance rover. Shortly afterwards, the 19-inch-tall (48-centimeter), 4-pound (1.8-kilogram) helicopter became the first powered aircraft to lift off from the surface of another planet. Although it was originally intended to perform just five test flights, Ingenuity kept on going, performing 72 flights and flying 14 times farther than planned for a total flight time of two hours.

    Things came crashing down for Ingenuity last year after the helicopter broke its blades while landing for the 72nd time, officially ending its mission in January 2024. Its mission more than exceeded expectations, delivering precious data on a new method of exploring the surface of another planet and opening up a new gateway for missions to Mars and elsewhere. Whatever chopper comes next will have some pretty big shoes to fill, so maybe sending six helicopters to Mars is the appropriate follow-up.

    Continue Reading

  • New Python Toolkit Automates Single-Cell Lineage Tracing, Accelerates Tumor Drug Resistance Analysis

    New Python Toolkit Automates Single-Cell Lineage Tracing, Accelerates Tumor Drug Resistance Analysis

    Researchers at Tsinghua University have released a novel Python toolkit, scLT-kit, which automates the processing and analysis of single-cell lineage tracing data, delivering clear insights into how individual cells develop, differentiate, and respond to treatments. Think of scLT-kit as a “GPS for cell genealogies”—it takes messy, high-dimensional data and plots each cell’s journey, making complex lineage relationships easy to follow. This tool addresses the growing need for flexible, user-friendly software to handle complex single-cell datasets.

    Novel Model to Decode Cell Dynamics Energises Regenerative Medicine and Cancer Research

    Understanding how cells change over time is crucial for fields ranging from regenerative medicine to cancer therapy. By making lineage tracing analyses more accessible, scLT-kit can accelerate research into tissue development, drug resistance, and disease progression. Its streamlined workflows could help biologists, pharmaceutical developers, and policymakers better evaluate how cells respond to treatments, ultimately informing new strategies for diagnosis and therapy.

    “With scLT-kit, we’ve improved a previously labor-intensive, bespoke analysis into a seamless, reproducible workflow,” says Prof. Jin Gu. “Our goal was to empower every lab—whether focused on development, drug resistance, or disease progression—to extract lineage insights from single-cell data in minutes, not months.”

    Automated Barcode Analysis Uncovers Predictable Developmental Clones—and Unruly Drug-Resistant Tumor Cells

    Through a series of analyses, the researchers uncovered the following insights:

    • scLT-kit reliably processes time-series single-cell RNA-seq data tagged with heritable barcodes, providing rapid quality checks and summary statistics of barcoding efficiency and clone sizes.
    • In developmental datasets (e.g., blood progenitors and C. elegans embryos), cells sharing the same barcode showed higher similarity in gene expression than unrelated cells.
    • In tumor cell lines treated with EGFR inhibitors (osimertinib or erlotinib), this within-clone similarity was less pronounced, reflecting the high heterogeneity of cancer persisters.
    • The toolkit computes measures of cell fate diversity, showing that normal development features more predictable outcomes, whereas drug-treated cancer cells exhibit greater randomness in fate decisions.
    • scLT-kit identifies subpopulations with distinct fate trajectories and uncovers genes linked to these fates through differential expression analysis.

    All-in-One Python Package Delivers Barcode QC, Lineage Networks and Interactive Sankey Plots

    scLT-kit combines standard single-cell RNA-seq processing with two specialized modules for lineage data. The scLT-statistics module calculates barcoding fractions and clone sizes at each time point. The scLT-analysis module builds lineage-based networks to infer how clusters of cells transition over time, visualizing dynamics with Sankey plots. Four quantitative indicators assess cell fate randomness and neighbor similarity. Finally, the package uses established statistical tests to link gene expression changes to specific fate outcomes, all within an easy-to-install Python package available on PyPI and GitHub.

    Streamlined Workflows Lower the Barrier to Single-Cell Lineage Tracing in Development and Disease

    scLT-kit brings robust, automated workflows to single-cell lineage tracing studies, lowering the barrier for labs to explore cell dynamics in development and disease. By integrating data quality checks, dynamic analysis, and gene-level insights, this toolkit promises to advance our understanding of how cells make fate decisions under both normal and perturbed conditions. The full study was published in Frontiers of Computer Science in April 2025 (https://doi.org/10.1007/s11704-025-41249-9).

    Frontiers of Computer Science (FCS) is a leading peer-reviewed international journal co-published by HEP and Springer Nature. FCS publishes papers in all major branches of computer science including (not limited to): Architecture, Software, Artificial intelligence, Theoretical computer science, Networks and communication, Information systems, Image and graphics, Information security, Interdisciplinary. Papers published in FCS include research articles, review articles, letters. FCS is indexed by SCI(E), EI, Scopus, et al. The Latest IF will be 4.8, Q1. It is also class B journal in the CCF recommended journals directory.

     


    Continue Reading